tbuckley/cabot-search huggingface dataset:
OS-026 CD4+T cells license Kupffer cells to produce IL-27 and reverse the CD8+T cell dysfunction induced by hepatocellular priming
Authors: Valentina Venzin, Cristian Beccaria, Chiara Perucchini, Pietro Delfino, Elisa Bono, Leonardo Giustini, Federica Moalli, Valeria Fumagalli, Marta Grillo, Chiara Laura, Pietro Di Lucia, Katharina Reinhard, Jutta Petschenka, Tana Omokoko, Sabrina Ottolini, Anna Celant, Keigo Kawashima, Micol Rava, Marco de Giovanni, Donato Inverso, Mirela Kuka, Patrick Kennedy, Martin Guilliams, Giulia Casorati, Ugur Sahin, Nina Le Bert, Fulvia Vascotto, Antonio Bertoletti, Luca Guidotti, Matteo Iannacone
Journal: Journal of Hepatology (2025)
OS-011-YI Comparison of diagnostic accuracy and utility of 10 non-invasive tests for clinically significant liver disease among a general population with metabolic dysfunction
Authors: Laurens A. van Kleef, Jesse Pustjens, Jörn M. Schattenberg, A.G. (Onno) Holleboom, Manuel Castro Cabezas, Maarten Tushuizen, Robert J. de Knegt, Arfan Ikram, Harry L.A. Janssen, Sven Francque, Willem Pieter Brouwer
Journal: Journal of Hepatology (2025)
OS-030-YI Discrepancies between self-reported alcohol intake and phosphatidylethanol in 2,925 individuals at risk of steatotic liver disease
Authors: Katrine Bech, Nikolaj Torp, Helle Schnefeld, Georg Semmler, Javier Vega, Katrine Prier Lindvig, Katrine Thorhauge, Stine Johansen, Ellen Lyngbeck Jensen, Ellen Elise Petersen, Johanne Kragh Hansen, Camilla Dalby Hansen, Ida Falk Villesen, Peter Andersen, Aleksander Krag, Mads Israelsen, Maja Thiele
Journal: Journal of Hepatology (2025)
GS-004 Development of portal hypertension after non-cirrhotic non-tumoral recent portal vein thrombosis (RPVT). A long-term follow-up study
Authors: Berta Bartrolí Alabau, Aurélie Plessier, Fabian Betancourt Sanchez, Audrey Payancé, Teresa Garcia Ballester, Laure Elkrief, Ainhoa Sánchez-Lorenzo, Hélène Larrue, Jesus Donate, Judit Vidal-González, Michael Praktiknjo, Carlos González-Alayón, Dhiraj Tripathi, Jose Fortea, Stefania Gioia, Carmen Álvarez-Navascués, Sarah Raevens, Elba Llop Herrera, Adonis Protopapas, Filipe Gaio Castro Nery, Tomás Artaza, Vincenzo La Mura, Anna Baiges, Isabelle Ollivier-Hourmand, Anna Darnell, Kamal Zekrini, Ernest Belmonte, Maria Ángeles García-Criado, Fanny Turon, Virginia Hernández-Gea, Xavier Verhelst, Oliviero Riggio, Angela Puente, Macarena Simón-Talero, Luis Téllez, Christophe Bureau, Edilmar Alvarado-Tapias, María Pilar Ballester, Pierre-Emmanuel Rautou, Juan Carlos García-Pagán
Journal: Journal of Hepatology (2025)
GS-009 Latest liver stiffness measurements predict liver-related outcomes in primary biliary cholangitis patients with discordant biochemical and liver stiffness responses
Authors: Yu Jun Wong, Laurent Lam, Pierre-Antoine Soret, Sara Lemoinne, Bettina E. Hansen, Gideon Hirschfield, Aliya Gulamhusein, Ellina Lytvyak, Albert Pares, Ignasi Olivas, María Carlota Londoño, Sergio Rodriguez-Tajes, John Eaton, Karim T. Osman, Christoph Schramm, Marcial Sebode, Ansgar Lohse, George Dalekos, Nikolaos Gatselis, Frederik Nevens, Nora Cazzagon, Alessandra Zago, Francesco Paolo Russo, Annarosa Floreani, Nadir Abbas, Palak J. Trivedi, Douglas Thorburn, Francesca Saffioti, Laszlo Barkai, Davide Roccarina, Vincenza Calvaruso, Anna Fichera, Adele Delamarre, Natalia Sobenko, Alejandra Villamil, Esli Medina-Morales, Alan Bonder, Vilas Patwardhan, Cristina Rigamonti, Marco Carbone, Pietro Invernizzi, Laura Cristoferi, Adriaan J. van der Meer, Ehud Zigmond, Eyal Yehezkel, Andreas E. Kremer, Ansgar Deibel, Tony Bruns, Karsten Große, Aaron Wetten, Jessica Dyson, David E. Jones, Keri-Ann Buchanan-Peart, Cynthia Levy, Atsushi Tanaka, Jérôme Dumortier, Georges-Philippe Pageaux, Victor de Lédinghen, Fabrice Carrat, Olivier Chazouillères, Christophe Corpechot, Aldo J. Montano-Loza
Journal: Journal of Hepatology (2025)
OS-051-YI Cathepsin B-mediated occludin degradation increases gut permeability and progression of alcohol-associated liver disease
Authors: Marcos F. Fondevila, Henriette Kreimeyer, Cynthia L. Hsu, Noemí Cabré, Tomoo Yamazaki, Aenne Harberts, Fernanda Raya Tonetti, Yongqiang Yang, Alvaro Eguileor, Abraham Stijn Meijnikman, Ricard Garcia-Carbonell, Vivian Hook, Jerrold R. Turner, Cristina Llorente, AlcHepNet Investigators, Thomas Reinheckel, David J. Gonzalez, Bernd Schnabl
Journal: Journal of Hepatology (2025)
GS-007-YI Novel “3-in-1” blood metabolomic test for the early diagnosis and risk stratification of primary sclerosing cholangitis and cholangiocarcinoma
Authors: Ainhoa Lapitz, Anne Echebarria, Ibon Martínez-Arranz, Piotr Milkiewicz, Marco Carbone, Rocio Macias, Cristina Alonso, Alejandro Montilla, Małgorzata Milkiewicz, Ahmed Fowsiyo, Mohamad Elgozair, Laura Izquierdo-Sánchez, Adelaida La Casta, Raul Jimenez-Aguero, Maria Jesus Perugorria, Laura Cristoferi, Johannes R. Hov, Christoph Schramm, Gonzalo Crespo, Marco Arrese, Javier Chahuan, Javier Bustamante, Angela Lamarca, Michael Dill, Domingo Balderramo, Luis Bujanda, Lewis Roberts, Tom Hemming Karlsen, Trine Folseraas, Pedro Miguel Rodrigues, Jesus Maria Banales
Journal: Journal of Hepatology (2025)
OS-021 Fontan-associated liver disease: clinical and epidemiological impact on a large cohort in the UK, a retrospective multicenter study
Authors: Eleonora Munaretto, Hannah Bellsham-Revell, Nathalie Dedieu, Aaron Bell, Mara Cananzi, Anil Dhawan, Michael Quail, Alastair Baker
Journal: Journal of Hepatology (2025)
OS-035-YI Gut colonization guided versus routine empiric antimicrobial therapy to manage infections in patients with cirrhosis: a pragmatic randomized trial
Authors: Nipun Verma, Jayant Agarwal, Samonee Ralmilay, Pratibha Garg, Archana Angrup, Shashi Vig, Arka De, Madhumita Premkumar, Sunil Taneja, Ajay Kumar Duseja, Nusrat Shafiq
Journal: Journal of Hepatology (2025)
Diagnostic Accuracy of Machine Learning Algorithms in Electrocardiogram-Based Sleep Apnea Detection: A Systematic Review and Meta-Analysis
Authors: Mustafa Eray Kilic, Mehmet Emin Arayici, Oguzhan Ekrem Turan, Yigit Resit Yilancioglu, Emin Evren Ozcan, Mehmet Birhan Yilmaz
Journal: Sleep Medicine Reviews (2025)
Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An <scp>EAACI</scp> Task Force Report
Authors: C. Mayorga, R. Fernandez‐Santamaria, G. E. Çelik, M. Labella, G. Murdaca, M. Sokolowska, D. Naisbitt, V. Sabato
Journal: Allergy (2025)

ABSTRACT Drug‐induced immune reactions are an important burden for patients and health systems. They can be classified into immediate‐drug hypersensitivity reactions (IDHRs) and delayed‐DHRs (DDHRs) based on their phenotype. Drugs do not always behave as allergens and need to bind to proteins, forming adducts. Therefore, IDHRs can be classified as antigenic (IgE, and IgG mediated) and nonantigenic immune responses (complement activation‐[CARPA], mas‐related G‐protein coupled receptor member X2 [MRGPRX2], cyclooxygenase [COX]‐1 and cytokine release reactions [CRRs]). DDHRs are even more complex due to the different cell subsets and mechanisms involved, showing both antigenic and nonantigenic immune responses too. Since different endotypes result in similar phenotypes, the establishment of specific biomarkers is essential for an accurate diagnosis, with important relevance for the management of patients, as well as for risk stratification. The biomarkers of clinical utility are skin tests, specific IgE (sIgE), tryptase, and some HLA‐DR genotyping. The diagnostic performance depends on the responsible drug. This review highlights that, unfortunately, most biomarkers have not gone beyond analytic or clinical validity. It is therefore important to set up multicentre translational studies to advance the validation process towards reaching a clinical utility phase.
Digital twins enable stratification of persistent atrial fibrillation patients for ablation diminishing unnecessary heart damage
Authors: Kensuke Sakata, Carolyna A P Yamamoto, Adityo Prakosa, Brock M Tice, Syed Yusuf Ali, Shane Loeffler, Eugene G Kholmovski, Sunil Kumar Sinha, Joseph E Marine, Hugh Calkins, David D Spragg, Natalia A Trayanova
Journal: npj Digital Medicine (2025)
Tumor microenvironment responsive nano-PROTAC for BRD4 degradation enhanced cancer photo-immunotherapy
Authors: Zheng Li, Guodong Ren, Xuewei Wang, Xiaowan Li, Lingwen Ding, Jianwei Zhu, Yajie Zhang, Chengwu Zhang, Jianhua Zou, Xiaoyuan Chen
Journal: Biomaterials (2025)
‘Comparing Large Language Models for antibiotic prescribing in different clinical scenarios’ – Author’s reply
Authors: Andrea De Vito, Nicholas Geremia, Davide Fiore Bavaro, Susan K Seo, Justin Laracy, Maria Mazzitelli, Andrea Marino, Alberto Enrico Maraolo, Antonio Russo, Agnese Colpani, Michele Bartoletti, Anna Maria Cattelan, Cristina Mussini, Saverio Giuseppe Parisi, Luigi Angelo Vaira, Giuseppe Nunnari, Giordano Madeddu
Journal: Clinical Microbiology and Infection (2025)
Reprogramming Mitochondrial Metabolism to Enhance Macrophages Polarization by ROS-Responsive Nanoparticles for Osteoarthritis
Authors: Yu-Song Yuan, Hui-Yun Li, Hao Lu, Gui-Cheng Li, Zheng Cao, Chun Xu, Hai-Hua Xiao, Ling-Pu Zhang, Hai-Lin Xu
Journal: Biomaterials (2025)
Acceptability and feasibility of research grade wearables for monitoring heat stress in Kenyan farmers
Authors: Daniel Kwaro, Stefan Mendt, Julius Okoth, Stephen Munga, Hanns-Christian Gunga, Zoë Hannah Heim, Ina Matzke, Aditi Bunker, Sandra Barteit, Martina Anna Maggioni
Journal: npj Digital Medicine (2025)

Abstract Sub-Saharan Africa faces increasing heat events due to climate change, affecting health and productivity. Wearable technology, though promising for monitoring these impacts, is underexplored in this region. This pilot study evaluated the acceptability and feasibility of research-grade wearables for monitoring heat stress among Kenyan subsistence farmers. In Siaya, 48 farmers (50% women) were monitored for 14 days using sensors to measure heart rate, core temperature, sleep, activity, and geo-location, alongside environmental data loggers for wet bulb globe temperature. Participants mostly rated their experience on a 5-point Likert scale and provided additional non-Likert feedback, with over 95% reporting high device likability and minimal disruption. Data availability was 88% for actigraphy and 100% for core temperature, with a median completeness of 100% for most devices. Women experienced greater heat strain than men. These findings demonstrate that research-grade wearables are acceptable and feasible for real-time heat stress monitoring in rural Africa.
High performance with fewer labels using semi-weakly supervised learning for pulmonary embolism diagnosis
Authors: Zixuan Hu, Hui Ming Lin, Shobhit Mathur, Robert Moreland, Christopher D Witiw, Laura Jimenez-Juan, Matias F Callejas, Djeven P Deva, Ervin Sejdić, Errol Colak
Journal: npj Digital Medicine (2025)

Abstract This study proposes a semi-weakly supervised learning approach for pulmonary embolism (PE) detection on CT pulmonary angiography (CTPA) to alleviate the resource-intensive burden of exhaustive medical image annotation. Attention-based CNN-RNN models were trained on the RSNA pulmonary embolism CT dataset and externally validated on a pooled dataset (Aida and FUMPE). Three configurations included weak (examination-level labels only), strong (all examination and slice-level labels), and semi-weak (examination-level labels plus a limited subset of slice-level labels). The proportion of slice-level labels varying from 0 to 100%. Notably, semi-weakly supervised models using approximately one-quarter of the total slice-level labels achieved an AUC of 0.928, closely matching the strongly supervised model’s AUC of 0.932. External validation yielded AUCs of 0.999 for the semi-weak and 1.000 for the strong model. By reducing labeling requirements without sacrificing diagnostic accuracy, this method streamlines model development, accelerates the integration of models into clinical practice, and enhances patient care.
Correction: SPOP‑mediated ubiquitination and degradation of PDK1 suppresses AKT kinase activity and oncogenic functions
Authors: Qiwei Jiang, Nana Zheng, Lang Bu, Xiaomei Zhang, Xiaoling Zhang, Yuanzhong Wu, Yaqing Su, Lei Wang, Xiaomin Zhang, Shancheng Ren, Xiangpeng Dai, Depei Wu, Wei Xie, Wenyi Wei, Yasheng Zhu, Jianping Guo
Journal: Molecular Cancer (2025)
Conserved Plasma Proteomics Signatures of Early Respiratory Outcomes Across COVID-19 and Non-COVID-19 Acute Respiratory Failure
Authors: N.A. Sathe, E.D. Morrell, I.B. Stanaway, L. Mabrey, G.L. Anesi, C.R. Barnett, D.M. Brett-Major, M.J. Broadhurst, J.P. Cobb, A. Irwin, V.K. Kumar, D.P. Landsittel, R.A. Lee, J.M. Liebler, K. Lutrick, V. Mukherjee, R. Postelnicu, L.N. Segal, J.E. Sevransky, A. Srivastava, D. Wyles, L.E. Evans, P.K. Bhatraju, M.M. Wurfel
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
A Single Dose of RT234, Vardenafil Inhaled via the Axial Oscillating Sphere Dry Powder Inhaler (AOS™ DPI), Acutely Improves Exercise Capacity and Reduces Dyspnea in Pulmonary Arterial Hypertension (PAH) Patients (WHO Group 1 PH) - Results From the Open-label Phase 2b CPET (Cardiopulmonary Exercise Testing) Study (NCT04266197)
Authors: R.L. Benza, P. Staehr, V. Franco, M.A. Aras, L.A. Spikes, D. Grinnan, H.B. Rossiter, C. Ferguson, E. Parsley, K. Feldkircher, T. Marmon, I. Preston
Journal: American Journal of Respiratory and Critical Care Medicine (2025)
Development and optimization of Eva1 (<i>MPZL2</i>) targeting chimeric antigen receptor T cells
Authors: Masahide Osaki, Seitaro Terakura, Shiho Hirano, Takuma Iwasa, Kanako C Hatanaka, Yutaka Hatanaka, Masaki Sunagawa, Toshio Kokuryo, Yoshitaka Adachi, Yuki Takeuchi, Ryo Hanajiri, Chie Sakanaka, Makoto Murata, Tomoki Ebata, Hitoshi Kiyoi
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Whereas chimeric antigen receptor gene modified T (CAR-T) cell therapy has been clinically applied to malignant lymphomas and multiple myeloma, CAR-T cell therapy for solid tumors has so far not reached clinical application. Epithelial V-like antigen 1 (Eva1), transcribed from myelin protein zero-like 2 (MPZL2), is a small surface protein highly expressed on various tumor cells. We selected Eva1 as a novel solid tumor-target antigen because of its broad expression across various tumor types. The purpose of the present study is to develop and optimize CAR-T cells targeting Eva1. Method We prepared various humanized single chain variable fragment sequences based on a mouse anti-human Eva1 monoclonal antibody. We constructed six humanized Eva1CAR-Ts and selected one that maintained specificity and good cellular proliferation after antigen stimulation. We further optimized the length of the extracellular spacer domain and the choice of the intracellular domain in vitro and in two different xenograft mouse models. Results We confirmed Eva1 expression on various tumor cell lines by flow cytometry and analysis of public database, but we also observed that normal monocytes weakly expressed Eva1. A combination of short spacer domain and 4-1BB or CD79A/CD40 intracellular domain provided higher treatment efficacy both in vitro and in vivo. The cytokine release on autologous monocyte stimulation to Eva1CAR-T cells was comparable to that on autologous B cell stimulation to CD19CAR-T cells. Humanized Eva1CAR-T cells demonstrated excellent therapeutic efficacy by infusing a single dose of Eva1CAR-T cells (1×10 6 ) in both NCI-H1975 lung cancer and CFPAC-1 pancreatic cancer cell line grafted model. Conclusions In summary, these data suggest that humanized Eva1CAR-T has promising therapeutic potential for the treatment of various Eva1-positive solid tumors. Regarding on-target/off-tumor recognition, further detailed analyses of the Eva1CAR-T cell responses to normal tissues are needed.
Novel cross-feeding human gut microbes metabolizing tryptophan to indole-3-propionate
Authors: Janina N. Zünd, Denisa Mujezinovic, Markus Reichlin, Serafina Plüss, Marina Caflisch, Serina Robinson, Christophe Lacroix, Benoit Pugin
Journal: Gut Microbes (2025)

Tryptophan-derived indoles produced by the gut microbiota, particularly indole-3-propionate (IPA), are key compounds associated with gastrointestinal balance and overall health. Reduced levels of IPA have been associated with inflammatory bowel disease, type 2 diabetes, and colorectal cancer. Since fiber-rich diets have been shown to promote IPA, we aimed to decipher fiber-specific effects and identify associated IPA-producing taxa in a range of healthy individuals. We cultured fecal microbiota from 16 adults with tryptophan and eight different dietary fibers and monitored community shifts by 16S rRNA gene amplicon sequencing and tryptophan-derived indoles using targeted liquid chromatography with diode array detection. The concentrations and types of indoles produced were donor-specific, with pectin strongly promoting IPA production in certain donors. IPA production was not associated with any known IPA producer but with the pectin-utilizing species Lachnospira eligens, which produced indole-3-lactate (ILA) in vitro, the IPA precursor. Supplementation of ILA in additional fecal microbiota cultures (n = 6) revealed its effective use as a substrate for IPA production. We identified a novel IPA producer, Enterocloster aldenensis, which produced IPA exclusively from ILA but not from tryptophan. Co-culture of L. eligens and E. aldenensis resulted in IPA production, providing new evidence for an ILA cross-feeding mechanism that may contribute to the IPA-promoting effects observed with pectin. Overall, we highlight the potential for targeted dietary interventions to promote beneficial gut taxa and metabolites.
Simulating mismatch between calibration and target population in AI for mammography the retrospective VAIB study
Authors: Haiko Schurz, Klara Solander, Davida Åström, Fernando Cossío, Taeyang Choi, Magnus Dustler, Claes Lundström, Håkan Gustafsson, Sophia Zackrisson, Fredrik Strand
Journal: npj Digital Medicine (2025)
PD-1 blockade employed at the time CD8+ T cells are activated enhances their antitumor efficacy
Authors: Jena E Moseman, Ichwaku Rastogi, Donghwan Jeon, Douglas G McNeel
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background We have previously shown that immune checkpoint receptors, including PD-1, are upregulated on T cells at the time of their activation, and that blockade of these receptors can improve the efficacy of antitumor vaccines. In the present study, we sought to determine whether, and by what mechanisms, the timing of PD-1 blockade with respect to vaccination affects antitumor T cell function. Methods TRAMP-C1 or E.G7-OVA tumor-bearing mice received PD-1 blockade at different timing intervals with a tumor-associated antigen vaccine. Tumor growth, survival, and immune-infiltrating populations were assessed. In vitro models of T cell activation using OT-I T cells and PD-(L)1 axis disruption with a PD-1 blocking antibody or PD-L1 KO dendritic cells were used. Results Mice receiving PD-1 blockade at the time of T cell activation with vaccine had better antitumor outcomes in comparison to mice receiving PD-1 blockade before or after immunization. T cells activated in vitro in the presence of PD-(L)1 axis disruption had a more differentiated, functional phenotype with decreased CD28 and CCR7 expression and increased production of the Tc1 cytokines IL-2, TNFα, and IFNγ. Intriguingly, a small subset of undifferentiated cells (CD28+) was of a stem-like Tc17 phenotype (IL-17α+, TCF1+). Tumor-bearing mice receiving T cells activated in the presence of PD-(L)1-axis disruption had better antitumor outcomes and a greater number of complete responses. Conclusions These data indicate that PD-1 blockade, when used with antitumor vaccines, acts primarily at the time of T cell activation, not exclusively within the tumor microenvironment. Consequently, PD-1 blockade may be best used when delivered concurrently with T cell activating agents such as vaccines.
Dual role of Metrnl: exercise-induced benefits and potential cancer implications
Authors: Hamid Alizadeh
Journal: Journal for ImmunoTherapy of Cancer (2025)

Metrnl (Meteorin-like), a protein elevated by exercise, supports metabolic regulation, inflammation reduction and glucose homeostasis. While exercise is a cornerstone of cancer prevention and management, recent findings suggest that Metrnl plays a dual role, potentially impairing T-cell function in the tumor microenvironment. This commentary explores the interplay between Metrnl’s systemic benefits and its local immunosuppressive effects in cancer. Despite these concerns, exercise remains broadly advantageous for patients with cancer, though further research is essential to understand Metrnl’s context-specific impacts.
BCL-2 mutant B7H6-CAR-T cells synergized with venetoclax for treating small cell lung cancer
Authors: Huihui Zhang, Liliang Xia, Wendi Xuzhang, Ziming Li, Junshi Zhang, Fanlin Li, Chen Cheng, Jiawen Wang, Xincheng Zong, Xuanming Yang, Shun Lu
Journal: Journal for ImmunoTherapy of Cancer (2025)

Background Patients with small cell lung cancer (SCLC) generally have a poor prognosis, with an exceptionally high proliferative rate and a strong propensity for early metastasis, indicating the urgent need for novel therapies. The development of chimeric antigen receptor (CAR)s targeting solid tumors is limited owing to the lack of target antigens and low efficacy. In this study, we aimed to discover new targets for SCLC CAR-T therapy and develop CAR-T-based combinational treatment against SCLC in preclinical models. Methods The in vitro antitumor activity of B7H6-specific CAR-T cell was evaluated. Venetoclax-resistant B7H6 CAR-T cell were designed and the synergistic effect of venetoclax and B7-H6 CAR-T cells was tested in vitro and in vivo. Result B7H6 is highly expressed in SCLC tumors. CAR-T cell against B7H6 displayed antigen-specific antitumor efficacy. BCL-2(D103E)-expressing CAR-T cells showed resistance to venetoclax-induced apoptosis. The combinational treatment of venetoclax and BCL-2(D103E)-expressing B7H6-targeting showed potent anti-SCLC effect in vitro and in vivo. Conclusions Our findings suggest that the combination of BCL-2 mutant-expressing B7H6-targeting CAR-T cells and venetoclax could be a promising novel strategy against B7H6-expressing SCLCs and other solid tumors, providing the foundation for CAR-T cells and proapoptotic small molecules therapy in patients with SCLCs in a clinical trial.